Natera, Inc. (US) acquired some assets regarding non-invasive prenatal and carrier screening business from Invitae (US).
The global liquid biopsy market, valued at US$3.65 billion in 2024, stood at US$4.03 billion in 2025 and is projected to advance at a resilient CAGR of 11.8% from 2025 to 2030, culminating in a forecasted valuation of US$7.05 billion by the end of the period. The increasing global cancer incidence and the growing emphasis on early and precise disease detection primarily drive this market expansion.
Liquid biopsy techniques enable real-time tumor monitoring and facilitate the tracking of resistance development to specific therapies, thereby providing crucial insights for physicians utilizing targeted cancer treatments. Furthermore, these tests are gaining traction in non-invasive prenatal testing and transplantation, broadening their clinical utility.
Additionally, technological advancements such as next-generation sequencing (NGS) and improved http://www.marketsandmarkets.com/Market-…et-43.html detection methods are enhancing the sensitivity and reliability of liquid biopsy tests. Furthermore, rising investments from both public and private sectors in precision medicine, coupled with a growing demand for early and non-invasive diagnostic solutions, are further propelling the adoption of liquid biopsy across various healthcare settings.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdown…opsymarket
By technology, the liquid biopsy market is segmented by technology into multi-gene parallel analysis using NGS and single-gene analysis using PCR & microarrays. In 2024, the multi-gene parallel analysis using NGS segment accounted for the largest share of the market.
The large share of this segment is attributed to NGS’s ability to analyze multiple genetic alterations simultaneously, offering comprehensive molecular profiling with high accuracy. Its high-throughput capacity, flexibility, and suitability for detecting complex genomic changes make it ideal for clinical applications such as therapy selection and monitoring.
The integration of NGS into personalized medicine strategies and its growing use in routine diagnostics further contribute to market growth.
By application, the liquid biopsy market is segmented into cancer and non-cancer applications. In 2024, the cancer applications segment accounted for the largest share of the market.
This dominance is primarily driven by the rising global incidence of cancer and the increasing volume of research focused on utilizing liquid biopsy in oncology. The segment’s growth is further supported by liquid biopsy’s ability to monitor tumor progression in real time, detect minimal residual disease, and overcome limitations associated with traditional tissue biopsies.
By geography, the liquid biopsy market is segmented into five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America accounted for the largest share of the market.
The large share of this market is attributed to the region’s well-established healthcare infrastructure, which includes advanced diagnostic capabilities, specialized cancer care centers, and a highly trained medical workforce. These factors collectively support the widespread adoption of liquid biopsy technologies and their integration into routine clinical practice, ensuring broader patient access across diverse healthcare settings.
Request Sample Pages : http://www.marketsandmarkets.com/request…opsymarket
By circulating biomarker type, the circulating tumor DNA (ctDNA) segment is expected to grow at the highest CAGR during the forecast period.
By circulation biomarker type, the market is segmented into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles, and other biomarkers. The ctDNA segment is expected to grow at the highest CAGR during the forecast period.
The high growth rate of this segment is attributed to the ctDNA’s ability to provide real-time insights into tumor genetics, enabling early cancer detection, treatment monitoring, and identification of resistance mutations. Its high sensitivity, non-invasiveness, and growing use in precision oncology and companion diagnostics make ctDNA a preferred biomarker in clinical practice and research applications.
By sample type, the blood sample segment is expected to dominate the market during the forecast period.
The market is segmented by sample type into blood samples and other sample types. The blood sample segment is expected to dominate the market during the forecast period.
The large share of this segment is attributed to the convenience, cost-effectiveness, safety, and minimally invasive nature of blood collection. Blood-based liquid biopsy assays have undergone extensive clinical validation and received regulatory approvals across multiple cancer types and clinical indications.
The proven reliability has established blood as the preferred sample for liquid biopsy testing in routine clinical practice.
Recent Developments of Liquid Biopsy Market
* In April 2025, Natera, Inc. (US) launched its ultra-sensitive Signatera Genome-MRD test in the US. * In February 2025, Myriad Genetics, Inc. (US) collaborated with Gabbi (US), a telehealth solution for breast cancer risk assessment & specialist care services. The companies will collaborate to provide an integrated offering that combines Gabbi’s risk assessment program and access to breast specialists with Myriad’s MyRisk with RiskScore Hereditary Cancer Test. * In February 2024, Myriad Genetics, Inc. (US) entered into a definitive agreement to acquire select assets from Intermountain Health. These included assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory.
News From
MarketsandMarkets™
Category: Industry Reports & Market Analysis Profile: About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, w …
This email address is being protected from spambots. You need JavaScript enabled to view it.
